BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26091705)

  • 21. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
    Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
    Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
    Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
    Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.
    Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP
    J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis.
    Evangelista L; Guarneri V; Conte PF
    Curr Radiopharm; 2016; 9(3):244-257. PubMed ID: 27774910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer
    Paquette M; Lavallée É; Phoenix S; Ouellet R; Senta H; van Lier JE; Guérin B; Lecomte R; Turcotte ÉE
    J Nucl Med; 2018 Feb; 59(2):197-203. PubMed ID: 28798032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Validity of 16α-[
    van Geel JJL; Boers J; Elias SG; Glaudemans AWJM; de Vries EFJ; Hospers GAP; van Kruchten M; Kuip EJM; Jager A; Menke-van der Houven van Oordt WC; van der Vegt B; de Vries EGE; Schröder CP;
    J Clin Oncol; 2022 Nov; 40(31):3642-3652. PubMed ID: 35584346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Head-to-Head Evaluation of
    Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
    J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
    Dehdashti F; Mortimer JE; Trinkaus K; Naughton MJ; Ellis M; Katzenellenbogen JA; Welch MJ; Siegel BA
    Breast Cancer Res Treat; 2009 Feb; 113(3):509-17. PubMed ID: 18327670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).
    Peterson LM; Kurland BF; Schubert EK; Link JM; Gadi VK; Specht JM; Eary JF; Porter P; Shankar LK; Mankoff DA; Linden HM
    Mol Imaging Biol; 2014 Jun; 16(3):431-40. PubMed ID: 24170452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
    Linden HM; Kurland BF; Peterson LM; Schubert EK; Gralow JR; Specht JM; Ellis GK; Lawton TJ; Livingston RB; Petra PH; Link JM; Krohn KA; Mankoff DA
    Clin Cancer Res; 2011 Jul; 17(14):4799-805. PubMed ID: 21750198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
    Kurland BF; Peterson LM; Lee JH; Schubert EK; Currin ER; Link JM; Krohn KA; Mankoff DA; Linden HM
    Clin Cancer Res; 2017 Jan; 23(2):407-415. PubMed ID: 27342400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
    Linden HM; Stekhova SA; Link JM; Gralow JR; Livingston RB; Ellis GK; Petra PH; Peterson LM; Schubert EK; Dunnwald LK; Krohn KA; Mankoff DA
    J Clin Oncol; 2006 Jun; 24(18):2793-9. PubMed ID: 16682724
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Liu C; Ma G; Zhang J; Cheng J; Yang Z; Song S
    Ann Nucl Med; 2023 Dec; 37(12):675-684. PubMed ID: 37787851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[
    Katzenellenbogen JA
    Nucl Med Biol; 2021 Jan; 92():24-37. PubMed ID: 32229068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.
    Peterson LM; Mankoff DA; Lawton T; Yagle K; Schubert EK; Stekhova S; Gown A; Link JM; Tewson T; Krohn KA
    J Nucl Med; 2008 Mar; 49(3):367-74. PubMed ID: 18287268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
    Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
    J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biodistribution of
    Iqbal R; Yaqub M; Oprea-Lager DE; Liu Y; Luik AM; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
    J Nucl Med; 2022 May; 63(5):694-699. PubMed ID: 34446451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET.
    Tsujikawa T; Yoshida Y; Kiyono Y; Kurokawa T; Kudo T; Fujibayashi Y; Kotsuji F; Okazawa H
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):37-45. PubMed ID: 20717823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.
    Fowler AM; Chan SR; Sharp TL; Fettig NM; Zhou D; Dence CS; Carlson KE; Jeyakumar M; Katzenellenbogen JA; Schreiber RD; Welch MJ
    J Nucl Med; 2012 Jul; 53(7):1119-26. PubMed ID: 22669982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-
    Ulaner GA; Mankoff DA; Clark AS; Fowler AM; Linden HM; Peterson LM; Dehdashti F; Kurland BF; Mortimer J; Mouabbi J; Moon DH; de Vries EGE
    J Nucl Med; 2023 Mar; 64(3):351-354. PubMed ID: 36863779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.